Advaxis — Investor Presentation (September 2017)
37 slides from Advaxis's investor presentation, Sep 25, 2017
Slide 1: Harnessing Lm Technology: Bringing New Treatments to Market
ADVAXIS Harnessing Lm Technology™ Bringing New Treatments to Market
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding Advaxis’ ability to develop and commercialize the next generation of cancer immunotherapies, and the safety and efficacy of Advaxis’ proprietary immunotherapies. Thes
Slide 3: Advaxis Immunotherapies
ADVAXIS IMMUNOTHERAPIES™ A late-stage biotechnology company creating cancer immunotherapies that enlist the body’s own immune system to fight cancer. Advaxis’ proprietary Lmtargeted immunotherapy is a new approach toward an effective cancer vaccine. Our Lm Technology has achieved safety and efficacy
Slide 4: Advaxis, Inc: Investment Snapshot
Advaxis, Inc: Investment Snapshot att woRBERAR eta + Platform based on attenuated Lm (Listeria Monocytogenes) + Multiple approaches to impacting the immune system * Manageable safety profile: common AEs are mostly mild to moderate and resolve within 48 hours *3clinical stage programs: HPV-Associated
Slide 5: Who is Advaxis? Company Overview
ADVAXIS IMMUNOTHERAPIES™ Who is Advaxis? Company Overview
Slide 6: Who is Advaxis?
Who is Advaxis? ADVAXIS Creating Next-Generation Cancer Immunotherapies, Using a Proprietary Lm Platform Q (5) a Products: HQ: Princeton, 4 clinical Nd, U.S.A. franchises eee 3 Cash on Partnerships: hand*:$89.4m, BMS, In-House (no debt); AstraZeneca, Manufacturing 41M shares Merck, Amgen Capabilitie
Slide 7: Experience and Expertise are Our Greatest Assets
Who is Advaxis? ADVAXIS Experience and Expertise are Our Greatest Assets Interim Chief Executive Officer ceveathcare cS AULA Chief Scientific Officer Chief Financial Officer Chief Operating Officer PHARMACIA Orseser @ Pharma AESGEN Amicus VP, Technical Operations Sr. VP, Product Development Sr. VP,
Slide 8: Our Differentiator: Lm Technology Platform
ADVAXIS IMMUNOTHERAPIES™ Our Differentiator: Lm Technology™ Platform,
Slide 9: Harnessing the Immune System with Lm Technology
Harnessingthe Immune System with Lm Technology™ ADVAXIS A Demonstrated, Personalized Next-Generation Cancer Immunot ull une Activation of both the innate and Attenuated listeriais unable to travel Enhanced potency of the immune Potential for combination synergies; adaptive T cell mediated responses,
Slide 10: The Power of Lm
Harnessingthe Immune System with Lm Technology ™ The Power of Lm Proprietary technology: protected by a range of patents, stretching into 2037 Clinically validated: unprecedented improvement of 12 month survival rates in Ph 2 metastatic cervical cancer studies, warranting confirmatory study Safety p
Slide 11: Lm Technology Platform: Unmet Needs in Immuno-Oncology
Lm Technology Platform: Unmet Needs in Immuno-Oncology 5 OS Today's Immunotherapy Landscape Lm Technology Complements the Landscape and Addresses Unmet Needs Checkpoint Inhibitors/Co-stimulatory Agonists: Impressive Successes in Recent Years - Combo therapy likely required for optimal treatment - No
Slide 12: Opportunity, Accomplishments & Company Direction
IMMUNOTHERAPIES™ Opportunity, Accomplishments & — Company Direction
Slide 13: The Future of Lm Technology: Next-Generation Cancer Immunotherapies
The Future of Lm Technology™ Next-Generation Cancer Immunotherapies Demonstrated Achievements in CC, Poised for Expansion to Major Cancers ADVAXIS Regulatory: FDA Orphan Designation: Anal, Head & Neck Cancers Clinical: Ph 2in India: 34.9% 12- month OS Regulatory: FDA Orphan designation Invasive CC E
Slide 14: Lm Technology's Three Unique Attributes
Lm Technology’s Three Unique Attributes: An Ideal Vector For Immunotherapy ¥ 5 Can grow along Can be adapted to with ping bd target many types A . f Lm Technology’s comprehensive immunotherapy Lm oreancer immune stimulation and priming Technology Unique Attributes redirects a “pathogen” response aga
Slide 15: Expansion of Lm Technology Beyond HPV: Four Key Franchises
Expansion of Lm Technology Beyond HPV: Advaxis Focus on Four Key Franchises HPV-Related Cancers The Proof of Concept HOT Expansion into the Most Common Cancer Types NEO Individualized Neoantigens Prostate Cancer
Slide 16: Expansion of Lm Technology Beyond HPV: Four Key Franchises
Expansion of Lm Technology Beyond HPV: Advaxis Focus on Four Key Franchises HPV-Related Cancers Individualized Neoantigen Therapy * Demonstrated safety and efficacy of axalimogene filolisbac (AXAL) — * Partnership with Amgen Inc. highest 12 mo. OS in metastatic CC as observed by GOG across . . oo, .
Slide 17: Clinical Trial Programs: In Progress and On the Horizon
The Future of Lm Technology™ ADVAXIS Clinical Trial Programs —In Progress and On the Horizon CANCER INDICATION PARTNER PHASE 1 PHASE 2 PHASE 3 High-Risk, Locally Advanced Cervical Metastatic Cervical Combination with IMFINZI™ (durvalumab) AstraZeneca Metastatic Cervical Combination with OPDIVO® (niv
Slide 18: Business Acceleration
Business Acceleration Multiple inflection points beginning in 2018 nts OGRAM MILESTONE RGET Metastatic Prostate Ph1/2 Combination with pembrolizumab ADXS-PSA Part A Monotherapy Completed Axalimogenefilolisbac | B9owrent | Metastatic, Cervical Cancer Q42017 ADXS-DUAL ee Cervical Ph 3 Combination with
Slide 19: Proof of Concept: HPV-Associated Cancers
IMMUNOTHERAPIES™ Proof of Concept: HPV-Associated » Cancers
Slide 20: Expanding Lm Technology into the Cervical Cancer Market
Expanding Lm Technology™ into the Cervical Cancer Market The Opportunity for Our HPV Franchise 39,800 4,210 new U.S. cancer cases per Geeinessom coxvicat 58,373 European women diagnosed with cervical cancer per year* 24,404 estimated deaths from cervical cancer per year in Europe* most common 12,820
Slide 21: Proof of Concept for Lm Technology
Proof of Concept for Lm Technology Phase 2 Study in India: Prolonged Survival and Tumor Response in Randomized, Multicenter Phase 2 Study in Recurrent/ Refractory CC Illustrated the Promise of Lm Technology’ v¥ 34.9% 12-month survival rate (38/109), 3 durable CRs observed GOG-0265: Unprecedented imp
Slide 22: Regulatory Pathway
Regulatory Pathway IMMUNOTHERAPIES™ ADVANCE Metastatic Combination Study with ADXS-DUAL and nivolumab Metastatic cervical cancer is an area of high unmet need Combination of ADXS-DUAL with nivolumab: significant opportunity to improve patient outcomes vs. standard of care ADXS-DUAL provides enhanced
Slide 23: Individualized Neoantigens
ADVAXIS IMMUNOTHERAPIES™ Individualized Neoantigens
Slide 24: Capitalizing on the Individualized Medicine Market with Lm Technology
Capitalizing on the Individualized Medicine Market with Lm Technology™ IMMUNOTHERAPIES™ Ss ADXS-NEO is designed to create truly individualized therapies by activating the patient's immune system to respond against their own unique mutations (neoantigens) within the tumor
Slide 25: ADXS-NEO to Patients
-NEO to Patients Massive Parallel Sequencing oftumor biopsies Patient-specific Patient’s Hospital or Immunotherapies Treating Institution Treat patientwith personalized immunotherapy vector programmedto his/her neoepitopes Advaxis designs vector based Identify neoepitopes onneoepitopes and bioengine
Slide 26: ADXS-NEO in Action
-NEOin Action IMMUNO Once injected into the patient, Lm Technology taken up by antigen- ee presenting cells Tumor-associated * antigens t Tcell Activated T cell APC presenting antigen to T cell 2. The bacteria secrete tumor-associated y Peso antigens into the liquid interior of the cyl NGLro) APC =)
Slide 27: Phase 1 Dose-Escalation Study of ADXS-NEO
Capitalizing on the Individualized Medicine Market with Lm Technology™ A Phase 1 Dose-Escalation Study of Advaxis (ADXS) NEO Expressing Personalized Tumor Antigens Endpoints Tumor Types: Dose — Primary: Metastatic Microsatellite Stable siete Tolerability/Safety Colon Cancer ; N=9-18 Expansion Phase
Slide 28: Further Expansion into Common Cancer Types: ADXS-HOT
IMMUNOTHERAPIES™ Further Expansion into Common Cancer Types: ADXS-HOT
Slide 29: Leveraging Lm Technology to Treat Most Common Cancers
Leveraging Lm Technology™ to Treat Most Common Cancers Introducing the ADXS-HOT Franchise ADXS-HOT immunotherapies combine multiple hotspot mutations (neoantigens), designed to increase potential for immunogenicity ADXS-HOT * Targets: Common (public or shared) “HotSpot” mutations in tumor driven gen
Slide 30: The Opportunity for ADXS-HOT
Leveraging Lm Technology™ to Treat Most Common Cancers The Opportunity for ADXS-HOT What is a “Hotspot” mutation?! 2 Cancers Ranked by “Hotspot” mutations? ¢ Growth of “Hotspot” mutations (i.e. somatic mutations) is one of the major mechanisms responsible for oncogenesis ¢ Genetic profiling of tumor
Slide 31: Expansion into Prostate Cancer
ADVAXIS Expansion into Prostate Cancer
Slide 32: The Opportunity in Prostate Cancer
Expanding/m Technology™ into the Prostate Cancer Market The Opportunity in Prostate Cancer of all new cancer cases in the men will die from U.S. are prostate cancer’ 1 61 5300 prostate cancer? of new prostate cancer cases estimated in the U.S. in 20171 26,730 1 F 7 deaths from prostate cancer In exp
Slide 33: ADXS-PSA Metastatic Prostate Cancer
ADXS-PSA Metastatic Prostate Cancer Phase 1/2 Combination with KEYTRUDA® (pembrolizumab) - (KEYNOTE-046) Inclusion Criteria: Part B Expansion: Endpoints = Progressive metastatic CRPC C2 MERCK « Safety = <2 prior systemic treatment regimens or <1 prior P Biles chemotherapeutic in the metastatic setti
Slide 34: ADXS-PSA Metastatic Prostate Cancer
ADXS-PSA Metastatic Prostate Cancer ADVAXIS Phase 1/2 Combination with KEYTRUDA® (pembrolizumab) - (KEYNOTE-046)
Slide 35: Upcoming Milestones
ADVAXIS Upcoming Milestones
Slide 36: Business Acceleration
Business Acceleration Multiple inflection points beginning in 2018 nts OGRAM MILESTONE RGET Metastatic Prostate Ph1/2 Combination with pembrolizumab ADXS-PSA Part A Monotherapy Completed Axalimogenefilolisbac | B9owrent | Metastatic, Cervical Cancer Q42017 ADXS-DUAL ee Cervical Ph 3 Combination with
Slide 37: Advaxis, Inc: Investment Snapshot
Advaxis, Inc: Investment Snapshot att woRBERAR eta + Platform based on attenuated Lm (Listeria Monocytogenes) + Multiple approaches to impacting the immune system * Manageable safety profile: common AEs are mostly mild to moderate and resolve within 48 hours *3clinical stage programs: HPV-Associated